Loading
Life sciences · Journal article
Pain Joints Spine · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Obesity, affecting approximately 40% of adults globally, remains inadequately managed by current pharmacotherapies, with most medications achieving weight loss plateaus and high discontinuation rates due to gastrointestinal adverse events. Maridebart cafraglutide, a bispecific molecule conjugating glucagon-like peptide-1 (GLP-1) receptor agonism with glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism, was developed to address these limitations through extended-acting kinetics and enhanced metabolic efficacy.Methods: This analysis synthesizes evidence from Phase 1 and Phase 2 clinical trials, mechanistic studies, and regulatory filings of maridebart cafraglutide conducted between 2022 and 2025. The Phase 2 trial (NCT05669599) enrolled 592 participants randomized to once-monthly doses (140, 280, or 420 mg), with or without dose escalation, or placebo across two cohorts: obesity without diabetes (n = 465) and obesity with type 2 diabetes (n = 127). The primary endpoint was percent change in body weight at 52 weeks. Secondary outcomes included glycated hemoglobin (HbA1c), waist circumference, blood pressure, lipid profiles, and high-sensitivity C-reactive protein (hs-CRP).Results: In the obesity cohort, maridebart cafraglutide achieved mean weight reductions of −12.3% to −16.2% (intention-to-treat) with the 420 mg every-4-week regimen, reaching up to −20% in efficacy analyses. The obesity–diabetes cohort demonstrated mean weight loss of −8.4% to −12.3%, accompanied by HbA1c reductions of 1.2 to 1.6 percentage points. No weight loss plateau was observed at week 52, suggesting additional efficacy potential with extended treatment. Dose escalation reduced gastrointestinal-related discontinuations from 12–17% to approximately 8%. Improvements in cardiometabolic parameters—including systolic blood pressure, triglycerides, and hs-CRP—paralleled weight loss. No unexpected safety signals were identified.Conclusion: Maridebart cafraglutide represents a significant advancement in obesity pharmacotherapy, combining robust efficacy with exceptional dosing convenience and a sustained weight loss trajectory. Its once-monthly formulation directly addresses adherence barriers inherent to weekly injection regimens, while its dual GLP-1R/GIPR mechanism confers metabolic advantages over existing monotherapies. The ongoing MARITIME Phase 3 program—encompassing cardiovascular, heart failure, sleep apnea, and renal outcomes—will define its position within the therapeutic hierarchy of incretin-based agents and its clinical utility across obesity-related comorbidities.